2026 Funding Opportunity RFP for Clinical Trials to Validate AI-Driven Drug Repurposing
Supports global clinical trials that use AI-generated data to repurpose approved drugs for new indications in unsolved or rare diseases.
Funder: Cures Within Reach
Due Dates: June 26, 2026: Letter of Intent (LOI) submission deadline (11:59pm US Eastern Time)
Funding Amounts: Up to $100,000 per project (includes required 10% institutional match); additional $5,000–$10,000 available for approved community engagement costs.
Summary: Supports global Phase I/IIA clinical trials validating AI-driven drug repurposing using already approved therapies for new indications in unsolved diseases.
Key Information: Only PIs from nonprofit academic/research institutions are eligible; AI-generated data must be included as preclinical support.
Description
This funding opportunity from Cures Within Reach supports investigator-initiated, proof-of-concept Phase I or IIA clinical trials that aim to validate the use of artificial intelligence (AI) in drug repurposing. The focus is on leveraging AI-generated data to identify and test already approved drugs, biologics, or eligible cellular/gene therapies for new indications in unsolved diseases. The program is open to principal investigators (PIs) at nonprofit academic or research institutions worldwide, with a preference for rare disease indications and off-patent therapies. The intent is to accelerate patient access to innovative treatments by bridging the gap between AI-driven predictions and clinical validation.
